Avacta Reports Progress in Oncology Drug Development; Getech Achieves Revenue Growth and Positive EBITDA
Avacta reported £16.9 million in cash as of December 31, 2025, following a £22.5 million equity raise to support its oncology drug development, including the upcoming clinical testing of its FAP-Exd (AVA6103) program. Meanwhile, Getech announced a successful turnaround, projecting a 6% revenue growth to £5 million and an adjusted EBITDA of £500,000 for the same fiscal year, driven by a new sustainable strategy and a 20% cost reduction.
Theia Market Signal Identification - AI Assisted
Avacta, a life sciences company based in Wetherby, reported unaudited cash and cash equivalents of £16.9 million as of December 31, 2025, supporting its clinical programs through Q3 2026. The company raised £22.5 million in equity during 2025 to fund its R&D initiatives.
Key developments include the anticipated clinical testing of its FAP-Exd (AVA6103) program and growth in its intellectual property portfolio. Getech, an energy resources company based in Leeds, announced a successful turnaround plan leading to a projected 6% revenue growth to £5 million for the fiscal year ending December 31, 2025, alongside an adjusted EBITDA of £500,000.
The firm implemented a new sustainable strategy focusing on Oil & Gas, Mining, and Natural Hydrogen, while reducing costs by 20%. Its order book stood at £3.8 million, and annual recurring revenue was reported at £2.8 million.
Comments